Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(9): e12563.
Published online 2010 September 3. doi:  10.1371/journal.pone.0012563
PMCID: PMC2933231

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors

Rafael Linden, Editor



In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR). Lovastatin attenuated ligand-induced receptor activation and downstream signaling through the PI3K/AKT pathway. Combining lovastatin with gefitinib, a potent EGFR inhibitor, induced synergistic cytotoxicity in a variety of tumor derived cell lines. The vascular endothelial growth factor receptor (VEGFR) and EGFR share similar activation, internalization and downstream signaling characteristics.

Methodology/Principal Findings

The VEGFRs, particularly VEGFR-2 (KDR, Flt-1), play important roles in regulating tumor angiogenesis by promoting endothelial cell proliferation, survival and migration. Certain tumors, such as malignant mesothelioma (MM), also express both the VEGF ligand and VEGFRs that act in an autocrine loop to directly stimulate tumor cell growth and survival. In this study, we have shown that lovastatin inhibits ligand-induced VEGFR-2 activation through inhibition of receptor internalization and also inhibits VEGF activation of AKT in human umbilical vein endothelial cells (HUVEC) and H28 MM cells employing immunofluorescence and Western blotting. Combinations of lovastatin and a VEGFR-2 inhibitor showed more robust AKT inhibition than either agent alone in the H28 MM cell line. Furthermore, combining 5 µM lovastatin treatment, a therapeutically relevant dose, with two different VEGFR-2 inhibitors in HUVEC and the H28 and H2052 mesothelioma derived cell lines demonstrated synergistic cytotoxicity as demonstrated by MTT cell viability and flow cytometric analyses.


These results highlight a novel mechanism by which lovastatin can regulate VEGFR-2 function and a potential therapeutic approach for MM through combining statins with VEGFR-2 inhibitors.


Angiogenesis is an important physiological process during fetal development and growth as well as in mature tissue remodeling and repair [1]. For cancer expansion and dissemination, both primary lesions and metastatic tumors must develop a new vascular supply in order to survive [1]. Angiogenesis is tightly regulated by balancing the activity of pro- and anti-angiogenic factors [2]. Multiple pathways contribute to tumor angiogenesis including vascular endothelial growth factor (VEGF), fibroblast growth factor, and platelet-derived growth factor [2]. Based on the central role of VEGF in tumor angiogenesis and growth, it has emerged as a promising therapeutic target for angiogenesis inhibition [3]. VEGF, a 35- to 45-kDa dimeric polypeptide, plays a critical role in normal and pathologic angiogenesis [3]. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factors 1 and 2 [4]. The VEGF-A gene, via alternative splicing, yields several isoforms, of which, VEGF165 plays a critical role in tumor angiogenesis [3]. Tumor cells secrete VEGF in response to many stimuli including hypoxia, low pH, or cellular stress, which are prevalent in most solid tumors [5].

VEGF exerts its biologic effect through interaction with receptors present on the cell surface. These receptor tyrosine kinases (RTK) include VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1), which are predominantly present on vascular endothelial cells [6]. Both VEGFR-1 and VEGFR-2 have an extracellular ligand binding domain, a transmembrane region, and a tyrosine kinase domain [2], [3]. In addition, VEGFR-3 (Flt-4) is expressed on vascular and lymphatic endothelium while the neuropilin receptor is expressed on vascular endothelium and neurons [2], [3]. VEGFR-2 is the main receptor responsible for mediating the proangiogenic effects of VEGF in tumor-associated endothelium [7]. VEGF binding to the extracellular domain of the VEGFR results in dimerization and autophosphorylation of the intracellular tyrosine kinases [8]. This activates multiple downstream proteins that play functional roles in cell survival, proliferation vascular permeability and stabilization of new blood vessels [8]. For example, VEGF induces endothelial cell proliferation by activating the protein kinase Ras-MEK-ERK pathway [8]. The pro-survival effects of VEGF/VEGFR-2 are mediated by the PI3K/AKT pathway [8]. Recent studies indicate that VEGFR are also expressed by some tumor cells and may represent an additional target [9].

Malignant mesothelioma (MM) is a highly aggressive tumor that arises from the surface serosal cells of the pleura and, less frequently, the peritoneum [10]. A strong link has been established between exposure to asbestos and increased risk for MM [11]. Treatment of MM with surgery, chemotherapy, or radiation therapy is rarely curative and median survival is in the range of 10–17 months [11]. Novel therapies for MM are needed. VEGF up-regulation appears to play an important role in mesothelial cell transformation. High levels of VEGF have been observed in the serum of MM patients and elevated pleural effusion VEGF levels are associated with poor survival in patients with MM [12]. VEGF may also act in a functional autocrine loop capable of directly stimulating the growth of MM cells [9]. MM cell lines express elevated levels of both VEGF and the VEGFR-1 and 2 compared with normal mesothelial cells [9]. VEGF activated these receptors and increased proliferation of all MM cell lines examined [9]. Interestingly, significant vascularization is rarely exhibited in MM suggesting that VEGF may play a key role in MM tumor progression by primarily regulating tumor cell proliferation suggesting VEGF/VEGFR as therapeutic targets in MM [10].

The rate-limiting step of the mevalonate pathway is the conversion of HMG-CoA to mevalonate, which is catalyzed by HMG-CoA reductase [13]. The mevalonate pathway produces various end products that are critical for many different cellular functions including cholesterol, dolichol, ubiquinone, isopentenyladenine, geranylgeranyl pyrophosphate (GGPP), and farnesyl pyrophosphate (FPP) [13]. Geranylgeranyl transferase and farnesyl transferase use GGPP and FPP, respectively, for post-translational modifications of a wide variety of cellular proteins including the Ras, Rab, and Rho families [14], [15]. These proteins regulate cell proliferation, intracellular trafficking and cell motility and this post-translational modification functions as a membrane anchor critical for their activity [14], [15]. Blockade of the rate-limiting step of the mevalonate pathway by HMG-CoA reductase inhibitors results in decreased levels of mevalonate and its downstream products [16] and, thus, may have significant influences on many critical cellular functions.

Malignant cells appear highly dependent on the sustained availability of the end products of the mevalonate pathway [17]. The statin family of drugs are potent inhibitors of HMG-CoA reductase that are widely used as hypercholesterolemia treatments [16]. Mevalonate metabolites are required for the proper function and localization of a number of downstream mediators of the VEGFR-2 signaling cascade [3], [18], [19], [20]. Proteins that require FPP or GGPP posttranslational modifications play critical roles in transducing these signals [3], [18], [19], [20]. In our recent studies, we have demonstrated that lovastatin treatment inhibits ligand-induced activation of EGFR [18], [21]. The mechanism by which EGFR inhibition is mediated by lovastatin is novel and suggests a previously unrecognized process controlling EGFR activity.

Due to the potential of lovastatin to target EGFR function and its downstream signaling, we previously evaluated the effects of combining lovastatin with the clinically relevant EGFR tyrosine kinase inhibitor (TKI) gefitinib [22]. The combination of gefitinib and lovastatin demonstrated significant co-operative cytotoxic effects when cells were pretreated with lovastatin for 24 hrs. At this time point, lovastatin demonstrated significant inhibition of EGFR function [21]. We demonstrated co-operative cytotoxic effects with this combination that was synergistic due to the induction of a potent apoptotic response [21]. In this study, we evaluated the potential of lovastatin to similarly inhibit VEGFR-2 function. Furthermore, we evaluated the effects of lovastatin on endothelial cell proliferation and survival as well as the effects of combining lovastatin with VEGFR-TKIs on MM tumor cell viability as a potential novel therapeutic approach.


Lovastatin inhibits internalization and degradation of the VEGFR-2

Previous studies have demonstrated that ligand binding to VEGFR-2 leads to receptor dimerization and autophosphorylation [8]. Autophosphorylation leads to the activation of its downstream signaling cascades and receptor internalization and degradation in lysosomes [8]. In this study, we evaluated the effect of lovastatin on VEGFR-2 internalization and degradation in VEGF treated HUVEC cells. Localization of VEGFR-2 was visualized by immunofluorescence staining. HUVEC cells were exposed to solvent control with or without treatment of 50 ng/ml VEGF165 for 30 min. In un-stimulated HUVEC cells, VEGFR-2 showed a dispersed staining pattern on the cell surface. With the addition of VEGF165, however, VEGFR-2 showed a distinct punctate intracellular staining pattern indicating efficient internalization of this receptor [23] in HUVEC (Figure 1A). Treatment of HUVEC with 2 µM lovastatin for 24 hrs showed a similar diffuse surface-staining pattern for VEGFR-2 as control cells. Addition of 50 ng/ml of VEGF165 for 30 min in lovastatin treated cells significantly reduced the punctuate intracellular staining pattern shown in control VEGF165 treated cells but displayed a similar diffuse staining pattern to control un-stimulated cells (Figure 1A).

Figure 1
Lovastatin treatment inhibits VEGFR-2 internalization.

To further examine whether lovastatin is regulating the internalization of the VEGFR ligand complex, we performed the Pinpoint Cell Surface Protein Isolation method that specifically labels and isolates proteins found on the cell surface. Cell surface proteins were biotinylated and isolated using immobilized avidin, prior to Western blotting with the VEGFR-2 antibody. As shown in Figure 1B, untreated HUVEC were found to have significant levels of VEGFR-2 expressed on the cell surface. As expected, stimulation with VEGF165 at 50 ng/ml for 30 min decreased the levels of VEGFR-2 on the cell surface (Figure 1B). In 2 µM lovastatin treated cells for 24 hrs, lower levels of surface expression of VEGFR were evident. This decrease may be the result of the inhibition of intracellular transport that is regulated in part by the geranylgeranylated rab protein family. Ligand stimulation did not affect VEGFR-2 surface expression in lovastatin treated cells indicative of inhibition of internalization. In untreated cells, actin was readily detected in the avidin pull downs while lovastatin treated cells had significantly lower levels (Figure 1B). These results suggest that in lovastatin treated HUVEC; surface protein binding of actin was inhibited. These results correspond well with recent studies that demonstrate a role for the actin cytoskeleton in the multi-step process of receptor internalization [24], [25].

Internalization of ligand bound VEGFR-2 often leads to its degradation in lysosomes as a way to attenuate its signal. To determine the effect of lovastatin on VEGFR-2 degradation, we performed Western blot analyses of total cellular protein extracted from VEGF165 stimulated HUVEC and H28 MM cells with or without lovastatin treatments. In HUVEC, the basal levels of VEGFR-2 were unchanged with or without 0.5, 1 and 5 µM lovastatin treatments for 24 hrs (Figures 1C and D). Control HUVEC cells stimulated with 50 ng/ml VEGF165 for 30 min demonstrated a significant decrease in VEGFR-2 protein levels indicating efficient degradation of ligand bound VEGFR-2 in these cells (Figures 1C and D). Treatment of HUVEC with 0.5, 1 and 5 µM lovastatin for 24 hrs attenuated the effect of VEGF165 addition on VEGFR-2 degradation as the levels of VEGFR-2 were significantly elevated in lovastatin-treated in comparison to control cells (Figures 1C and D). Ponceau Red staining of the membranes confirmed equal loading between samples and the area of the blot shown corresponds to the area where VEGFR-2 migrated. These results indicate that lovastatin treatment inhibits ligand-induced internalization and degradation of VEGFR-2 in HUVEC and H28 MM cells.

Based on lovastatin's ability to inhibit ligand-induced internalization of VEGFR-2, we further evaluated the effect of lovastatin treatment on the signaling cascades triggered by VEGFR-2 activation. The PI3K/AKT signaling pathway plays a significant role in cell survival responses mediated by VEGFR-2 [3]. Ligand bound VEGFR-2 activates PI3K that phosphorylates the phospholipid PIP2 resulting in the accumulation of PIP3 that in turn activates AKT [26]. Serum starved H28 MM derived cell line and HUVEC cells were treated with 0, 1, 10 and 25 µM lovastatin for 24 hrs followed with 50 ng/ml VEGF165 stimulation for 30 min. The functional activation of this pathway was evaluated by Western blot analysis, employing phospho-specific antibody recognizing the active form and control antibody for total AKT. Lovastatin treatment inhibited activation of AKT in a dose dependent manner that was readily detectable at the 1 µM dose in HUVEC but was less efficient in inhibiting AKT activation in H28 cells (Figure 2). There are a wide variety of AKT targets that regulate its effects on protein translation, proliferation and cell survival. These targets include ribosomal S6 kinase (S6K1) and eukaryotic translation initiation factor 4E (eIF4E) that regulate translation [27]. We evaluated the effects of lovastatin on ligand-induced activation of these proteins in our 2 model cell lines. Western blot analysis determined the effects of 0, 1, 10 and 25 µM lovastatin treatment for 24 hrs with 30 min 50 ng/ml VEGF addition on these AKT targets. Lovastatin treatment significantly inhibited phosphorylation of S6K1 (not detected in HUVEC) and 4EBP1 in a dose dependent manner (Figure 2). Activated phosphorylated AKT, S6K1 and 4EBP1 were not detected in serum starved control cells (data not shown). These results demonstrate the ability of lovastatin to readily inhibit VEGF induced AKT activation in these cell lines.

Figure 2
Lovastatin inhibits VEGF induced activation of AKT and its downstream targets.

Lovastatin induces cytotoxicity of HUVEC and MM Cells

Due to the regulation of cell viability by the AKT pathway, we evaluated the effects of lovastatin treatment on HUVEC and H28 cell viability. Cell viability assays based on trypan blue exclusion cell counts of HUVEC and H28 cells were evaluated at 72 hrs. The effect on cell viability of exogenous addition of VEGF165 was included in this study to determine the role of this pathway in regulating lovastatin-induced cytotoxicity. Treatment with lovastatin alone at 0.5, 1, 2 and 5 µM concentrations resulted in a dose-dependant decrease in the percentage of viable cells (Figures 3A and B). VEGF165 proliferative effects were observed in control cells (Figures 3A and B). The addition of VEGF165 to lovastatin treated cells inhibited lovastatin induced cytotoxicity at the low 0.5 and 1 µM lovastatin doses but this compensatory effect was reduced or eliminated at the higher 2 and 5 µM lovastatin treated cells (Figures 3A and B). The percentage of apoptotic HUVEC 72 hrs (Figure 3B) post-treatment was assessed using propidium iodide flow cytometry to study the effects of lovastatin in inducing apoptosis. The control cells showed a sub-G1 peak in the DNA histogram that is characteristic of apoptotic cells representing approximately 26% of cells analyzed, while addition of VEGF165 resulted in a reduction of apoptotic cells to approximately 13%, highlighting the role of VEGF in promoting HUVEC cell survival. At a dose of 1 µM and 2 µM, lovastatin induced significant apoptosis above the levels of that observed in the control cells. However, for the 1 µM lovastatin concentration, VEGF165 was still able to able to diminish the apoptotic effects of lovastatin on HUVEC but with the higher 2 µM lovastatin dose, addition of VEGF165 had no significant affect on the induction of apoptosis (Figure 3B). The cell viability and flow cytometric analyses show the ability of lovastatin to induce a potent apoptotic response in HUVEC that at lower doses can be rescued by VEGF but not at the higher doses relevant for use of lovastatin as an anti-cancer therapeutic [28], [29].

Figure 3
VEGF can partially rescue the cytotoxic and apoptotic effects of lovastatin.

Lovastatin affects cytoskeleton organization and RhoA Activity

Actin cytoskeletal organization is known to play a significant role in the internalization and intracellular trafficking of RTK including VEGFRs. RhoA and cdc42 regulate actin cytoskeleton architecture and are activated by VEGF to control cell shape and motility [23]. RhoA and cdc42 are GGPP modified proteins whose function can be inhibited by lovastatin treatment [15]. Lovastatin induced dramatic changes in the actin cytoskeletal organization of HUVEC. Treatment with 0.5, 2 and 5 µM lovastatin for 24 hrs, resulted in a significant reduction of F-actin fibers stained with rhodamine-conjugated phalloidin and these fibers appeared disorganized (Figure 4A). In HUVEC and H28 MM cells, treatment with 0.5, 1 and 5 µM lovastatin for 24 hrs induced a dramatic up-regulation of both rhoA and cdc42 protein levels (Figure 4B). Cyclin D1 is a regulator of cell cycle progression and is up-regulated by a wide variety of cellular signaling pathways including rhoA activation [30]. The significant increase of rhoA protein levels did not result in up-regulation cyclinD1 protein levels but were reduced with lovastatin treatment of HUVEC and H28 cells (Figure 4B). Furthermore, employing a colorimetric rhoA activation assay, we determined the effect of lovastatin on VEGF165 induced rhoA activation in HUVEC and H28 cells. Serum starved cell extract represent inactive levels of rhoA while 0.2M GTP loaded extract represents fully active rhoA. As expected VEGF stimulation induced rhoA activity to approximately 60% of the GTP loaded activity. Lovastatin (10 µM, 24 hrs) inhibited VEGF165 induced rhoA activation in both HUVEC and H28 cells while co-administration of mevalonate (100 µM) and GGPP (10 µM) reversed the inhibitory effects of lovastatin (Figure 4C). These results demonstrate that lovastatin-induced rhoA is inactive likely due to the lack of GGPP modification.

Figure 4
Lovastatin treatment results in actin disorganization and inhibits VEGF induced rhoA activation.

Inhibition of the VEGFR augments lovastatin-induced apoptosis

Our previous studies have demonstrated that the combination of lovastatin and EGFR-TKI have resulted in synergistic cytotoxicity in a variety of human cancer derived cell lines [21]. Other studies have demonstrated the utility of combining EGFR-TKI with downstream inhibitors of the AKT pathway including rapamycin. Mammalian target of rapamycin (mTOR) plays a central role in regulating AKT driven translation initiation by regulating S6K1 and 4EBP1 activity [31]. Rapamycin has limited clinical activity due to a feedback loop that activates AKT and acquired resistance [31] suggesting that lovastatin may represent a novel therapeutic approach to target this pathway and enhance RTK-TKI activity. In this study, we evaluated the ability of rapamycin or lovastatin to augment the effects of the VEGFR-2 inhibitor KRN633. The H28 MM cell line had a relatively weak response to lovastatin-induced AKT inhibition. H28 cells express both VEGF and VEGFR-2. By Western blot analysis of activated AKT and its downstream targets S6K1 and 4EBP1, KRN633 and rapamycin treatments alone had minimal effects on the activation of these proteins. The combination of these agents showed enhanced inhibition of this pathway (Figure 5). In contrast, lovastatin treatment alone inhibited AKT, S6K1 and 4EPB1 phosphorylation and the combination of lovastatin and KRN633 induced a dramatic inhibition of the AKT pathway in this MM derived cell line (Figure 5).

Figure 5
Lovastatin in combination with VEGFR-2 TKIs inhibits ligand induced activation of AKT, S6K1 and 4EBP1.

We further evaluated the combination of lovastatin and VEGFR-2 TKI on tumor cell cytotoxicity in HUVEC and MM cells. Utilizing MTT analysis and propidium iodide flow cytometry, we investigated the effects of combining two different VEGFR-TKIs with lovastatin on the viability of the H28 and H2052 MM derived cell lines and HUVEC. KRN633 inhibits VEGFR 1, 2 and 3 with similar kinetics while ZM323881 is highly selective for VEGFR-2 [32], [33]. With both MM derived cell lines and in HUVEC, increases in the concentration of the VEGFR-TKIs, KRN633 and ZM323881, resulted in a dose dependent decrease of MTT activity (Figure 6A). The pre-treatment of either 5 µM or 10 µM lovastatin for 24 hrs prior to the addition of 0–25 µM concentrations of the VEGFR-TKIs for 48 hrs resulted in co-operative cytotoxicity in both MM cell lines and HUVEC treated with either VEGFR-TKI (Figure 6A). The use of the Combination Index (CI) isobologram method of analysis [34] allowed for the determination of the effects of the combination of the lovastatin and VEGFR-TKIs (Figure 6B). CI values of <1, 1, and >1 are indicative of synergism, additive effect, and antagonism, respectively. The H28 MM cell line at the therapeutically relevant 5 µM dose of lovastatin resulted in a CI value of 0.58 for the combinatorial treatment of lovastatin and ZM323881, but the combination of lovastatin and KRN633 obtained a CI value of 1 (Figure 6B). The H2052 MM cell line and HUVEC had CI values of less than one for both VEGFR-TKIs. These results indicate that combining lovastatin with VEGFR-TKIs consistently induced synergistic cytotoxicity in MM and HUVEC cells.

Figure 6
Combining lovastatin with VEGFR-2 TKIs induces synergistic cytotoxicity in MM cells and HUVEC.

To determine if this combination based approach resulted in enhanced apoptosis, we assessed MM cells treated with 5 µM or 10 µM of the VEGFR-TKIs alone or in combination with 5 µM lovastatin using the same experimental conditions as above. In both cell lines, with both VEGFR-TKIs tested, the combination with 5 µM lovastatin with 5 µM and 10 µM of the VEGFR-TKIs induced a more potent apoptotic response than either agent alone. Representative results for the H2052 cell line using the inhibitor KRN633 are shown (Figure 6C) and demonstrate a significant increase in apoptosis of the cells when the treatments were combined. Lovastatin treatment (5 µM) induced an apoptotic response that was significantly enhanced in combination with 10 µM KRN633 treatments (Figure 6C). Thus, the synergistic cytotoxicity observed with the combination of lovastatin and VEGFR-TKIs in MM cells is accompanied by a potent apoptotic response.

To further demonstrate the role of VEGFR-2 as a target of these VEGFR-TKIs in the synergistic cytotoxicity observed in combination with lovastatin in MM cells, we specifically targeted the expression of VEGFR-2 employing short inhibitory RNA sequences (siRNAs). Employing the MTT cell viability assay, we demonstrated that while the siControl treatments (50 nM 48 hrs, followed by 48 hrs lovastatin treatment) had no effect on lovastatin treatments (1 and 5 µM) compared to reagent alone, siVEGFR-2 (50 nM 48 hrs, followed by 48 hrs lovastatin treatment) significantly enhanced lovastatin-induced cytotoxicity in H2052 and H28 MM cells (Figure 6D). Western blot analysis confirmed the specificity of the siRNAs employed as siVEGFR-2 but not siControl targeted VEGFR-2 expression at 48 and 96 hr treatments (Figure 6D).


In our previous study, we demonstrated that the targeting of HMG-CoA reductase, which results in mevalonate depletion [16], can inhibit the function of the EGFR [21]. Furthermore, combining lovastatin with gefitinib, an EGFR-TKI, induced apoptotic and cytotoxic effects that were synergistic. This was demonstrated in several types of tumor cell lines and potentially involved the PI3K/AKT pathway [21]. The mechanisms regulating the inhibitory effects of lovastatin on EGFR function and the synergistic cytotoxicity in combination with gefitinib are currently not known. These findings suggest that mevalonate pathway inhibitors and receptor TKI may represent a novel combinational therapeutic approach in a variety of human cancers. The VEGFR and the EGFR are both members of RTK family that share similar activation, internalization and downstream signaling characteristics [3], [35]. Therefore, targeting the mevalonate pathway may have similar inhibitory effects on VEGFR and may also enhance the activity of VEGFR-TKI. VEGFR, particularly VEGFR-2, play important roles in regulating angiogenesis by promoting endothelial cell proliferation, survival and migration [7]. VEGF and VEGFR are also expressed by some tumor cells, like MM, acting in a functional autocrine loop capable of directly stimulating the growth and survival of MM cells [9].

In this study, we have shown lovastatin does indeed inhibit ligand-induced VEGFR-2 activation through inhibition of receptor internalization resulting in diminished AKT activation in HUVEC and MM cells. Lovastatin treatment re-organized the actin cytoskeleton, inhibited proliferation and induced apoptosis of HUVEC at therapeutically relevant doses (<5 µM) [29] despite addition of exogenous VEGF. AKT activation, which mediates cell survival, along with its downstream targets S6K1 and 4EBP1 were significantly inhibited by lovastatin treatment. Combining lovastatin with VEGFR-TKIs also induced synergistic cytotoxicity of HUVEC cells. Due to their role in promoting tumor neovascularization, inhibiting the function of VEGF and VEGFR has been the focus of a number of therapeutic approaches [1]. The limited clinical responses associated with these agents have been associated with their ability to promote disease stabilization and rarely induce tumor regression [1], [36]. Thus, agents that can co-operate and enhance the activity of VEGFR-TKI, like lovastatin, may increase their therapeutic activity.

MM is a highly aggressive tumor that is rarely curative and median survival is in the range of 10–17 months [11], therefore, novel therapies for MM are needed. Elevated levels of circulating and serousal VEGF in MM patients and the expression of VEGF and VEGFR on MM cells that can drive their proliferation and enhance their survival [9] has led to the evaluation of VEGFR targeted therapies. Bevacizumab, a monoclonal antibody against the VEGF, which is approved for the treatment of colon cancer, in combination with chemotherapy, failed to significantly affect outcome to chemotherapy treatment alone [37]. Various VEGFR-TKI employed a single agents also failed to demonstrate clinical utility in MM patients [37]. As like HUVEC, MM cells also depend on VEGFR signaling, we also examined the effect of lovastatin alone and in combination with VEGFR-2 TKI on MM cell viability. Combining 5 µM lovastatin treatments with two VEGFR-2 inhibitors in the H28 and H2052 mesothelioma derived cell lines demonstrated synergistic cytotoxicity through the induction of a potent apoptotic response. These results highlight a novel mechanism regulating VEGFR-2 function and a potential novel therapeutic approach for MM.

Inhibition of HMG-CoA reductase has been evaluated as an anti-cancer therapeutic approach owing to its ability to inhibit tumor cell proliferation, induce tumor specific apoptosis and inhibit cell motility and metastasis in several tumor models [38][41]. A number of Phase I Clinical trials evaluating the efficacy of high doses of lovastatin failed to demonstrate significant anti-tumor activity [29]. The tumor types evaluated in these studies did not include those that we identified as being highly sensitive to lovastatin-induced apoptosis, including head and neck squamous cell carcinomas and cervical carcinomas [39]. As a result, a Phase I clinical evaluation of lovastatin in recurrent head and neck squamous cell carcinomas and cervical carcinoma patients was undertaken by our group. Although no tumor regressions were observed, 23% of patients exhibited stable disease [28]. Taken together, the most effective use of lovastatin and VEGFR-TKI would be as part of a combined modality approach.

Due to the potential for mevalonate metabolite depletion to functionally alter the VEGFR signaling pathway, HMG-CoA reductase and VEGFR targeted therapies may be associated. This study has shown that the combination of lovastatin with two VEGFR-TKIs induced significant co-operative cytotoxicity in both MM cell lines tested. More detailed isobologram analysis demonstrated that this enhanced cytotoxic response was synergistic. These results suggest the potential of combining these two therapeutic approaches. The inhibition of mevalonate synthesis and the depletion of one or more mevalonate metabolites is the mechanism regulating this phenomenon. The combination of statins and VEGFR-TKI represents an attractive therapeutic approach as clinical trials have shown a different spectrum of toxicities with these agents [29], [36]. In a recent manuscript, we have demonstrated similar inhibition of EGFR function by lovastatin in squamous cell carcinoma cells [42]. While in vivo murine tumor models evaluating the efficacy of statins have been employed, differences in drug metabolism between species and lack of target validation in many studies suggests the potential of off target effects playing a role in statin response [43], [44], [45]. To circumvent these issues, we evaluated the BR.21 NCIC-CTG Phase III clinical trial of the EGFR-TKI inhibitor tarceva as a single agent in non-small cell lung carcinoma patients [46]. In this trial, patients on erlotinib that were also taking statins to treat hypercholesterolemia had a trend to better outcomes than patients on erlotinib alone [42]. These studies have led to a Phase I/II clinical trial at our institute combining cerivastatin and erlotinib that is currently accruing patients ( Identifier: NCT00966472). Similar data for statin usage in VEGFR-TKI treated MM patients were not available due to the lack of a sufficient patient population for analysis. The ability of lovastatin to inhibit both EGFR and VEGFR function is intriguing and requires further study to elucidate its underlying mechanism. This suggests the potential for HMG-CoA reductase inhibition to affect the activity of a number of RTK potentially through a similar, novel and as yet uncharacterized mechanism.

Ethical Statement

Not applicable with respect to this study.

Materials and Methods

Tissue Culture

Human Umbilical Vein Endothelial Cells (HUVEC) (Clonetics, lot 2F1276, Walkersville, MD) were maintained in EGM-2 media supplemented with 2% fetal bovine serum provided in the EGM-2 Single Quot Kit Supplements and Growth Factors (Lonza, East Rutherford, NJ). The human mesothelioma lines, NCI-H28 and NCI-H2052, were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in HyQ DMEM/High Glucose (HyClone, Logan, Utah) supplemented with 10% fetal bovine serum (Medicorp, Montreal, QC). The cell lines used in this study were exposed to solvent control or lovastatin (provided by Apotex, Mississauga, ON; diluted from a 10mmol/L stock in ethanol), or human recombinant VEGF165 (provided by National Cancer Institute, Rockville, MD; reconstituted to a 50 mg/ml stock in deionized water) at a concentration of 50 ng/ml. The mesothelioma cell lines were exposed to solvent control or VEGFR-2 Inhibitor V, ZM323881, or VEGFR-TKI III, KRN633 (Calbiochem; both reconstituted to a 1mmol/L stock in DMSO). The siRNA oligonucleotides used in this study were purchased from Dharmacon (Boulder, CO). siControl: siGENOME non-targeting siRNA, siVEGFR-2: siGENOME SMARTpool human KDR. Transfection procedures were performed with DharmaFECT-4 reagent (Dharmacon) in both H28 and H2052 cells according to the manufacturer's protocols. Cells were grown on 6-well plates or 96-well plates and transfected with 50 nM of the siRNAs. After two days incubation, cells were treated with media or 10 µM lovastatin for another 48 hrs. The cytotoxic effects of lovastatin remained consistent in all three cell lines throughout the course of these experiments.

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay (MTT Assay)

In a 96-well, flat-bottomed plate (Fisher, Mississauga, ON), ~7500 cells/150 µl of cell suspension were used to seed each well. The cells were incubated overnight to allow for cell attachment and recovery. Following a 48- or 72-hr treatment of lovastatin, ZM323881, KRN633, or a combination of lovastatin and a VEGFR-TKI, 42 µL of a 5 mg/ml solution in PBS of the MTT substrate (Sigma) was added and incubated for up to one hr at 37°C. The resulting blue-brown formazan precipitate formed was solubilized by the addition of 84 µL of a 0.01M HCl/10%SDS (Sigma) solution and incubated for 8 hrs at 37°C. The plates were then analyzed on a Dynex Technologies MRX Microplate Reader at 570 nm using the Revel software (Dynex Technologies, Chantilly, VA) to determine the absorbance of the samples. Treatments were performed in replicates of six and the means expressed as the percent viability relative to the untreated control (100% viable). Statistical analysis: Combination Index (C.I.) was determined by the method of Chou and Talalay as previously described [34]. P values were determined by standard paired T-test evaluations.

Cell Viability Assay

In a 6-well flat-bottomed plate (Fisher), ~500000 HUVEC were used to seed each well. The cells were incubated overnight to allow for cell attachment and recovery. Following 72 hr treatment using solvent control or lovastatin in the presence or absence of 50 ng/ml VEGF165, the cells were trypsinized and collected. The number of viable cells in 500 µl of each sample was subsequently counted on the Beckman Coulter Vi-Cell-XR Cell Viability Analyzer (Mississauga, ON). Treatments were performed in triplicates. Data were normalized to the untreated control.

Propidium Iodide Flow Cytometry

In 10-cm plates (Fisher), ~3.5×105 mesothelioma cells or ~5×105 HUVEC were used to seed each plate. The plates were incubated overnight to allow for cell attachment and recovery. The HUVEC were treated with solvent control or lovastatin, in the presence or absence of 50 ng/ml VEGF165 for 72 hrs. The mesothelioma cells were treated with solvent control or lovastatin. Following a 24-hour pre-treatment with lovastatin alone, solvent control or VEGFR Inhibitor (KRN633 or ZM323881) was added for an additional 48 hrs. After the desired treatment length, the media, PBS wash and trypsinized cells were collected in the same 50 mL conical tube. The collected cells were fixed with 80% ethanol and incubated at −20°C for a minimum of 24 hrs. The cells were washed once then resuspended in staining buffer containing 50 µg/ml propidium iodide (Sigma) and 100 µg/ml RNaseA (Invitrogen, Carlsbad, CA). Ten thousand cells were evaluated using the Beckman Coulter Epics XL Flow Cytometer and the percentage of cells in pre-G1 phase was determined using the ModFit LT program (Verity Software House, Topsham, ME).

Western Blot Analysis

Total cellular protein was extracted using a buffer that consisted of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.25% sodium deoxycholate (Sigma), 1% IgePal, 0.1% SDS (Sigma), 1 mM EDTA, 5 mM sodium fluoride (Sigma), 1 mM sodium orthovanadate (Sigma), and protease inhibitor cocktail (Sigma; diluted from a 10× stock). Approximately 100 µL of extraction buffer was used per plate. Total protein was quantified with the BCA Protein Assay Reagents (Pierce, Nepean, ON) using bovine serum albumin (Sigma) for the standard. Protein extracts representing 50 to 100 µg total protein were separated on SDS-PAGE gel using the BioRad Mini Protean 3 System (Bio-Rad Laboratories, Hercules, CA) and electro-blotted onto Hybond P PVDF membranes (Amersham, Piscataway, NJ). Membranes were blocked in 5% skim milk powder in PBS/0.02% Tween (Sigma) for an hour at room temperature. Primary antibody, diluted in 5% skim milk powder in PBST, was incubated with the membrane overnight at 4°C. The primary antibodies used were specific for VEGFR-2, RhoA, cdc42, cyclinD1 (Santa Cruz Biotechnologies, Santa Cruz, CA); phospho-AKT, AKT, phospho-S6K1, S6K1, phospho-4EBP1, 4EBP1 (Cell Signaling Technology, Danvers, MA); and actin (Sigma). The peroxidase-conjugated AffiniPure Goat Anti-mouse/rabbit IgG (Jackson ImmunoResearch, West Grove, PA) secondary antibodies were applied at a 1[ratio]5000 dilution and the peroxidase-labeled Affinity Purified Antibody to goat IgG (KPL) secondary antibody was applied at a 1[ratio]1000 dilution in 5% skim milk powder in PBST and incubated for a minimum of an hour at room temperature then processed for detection with the Supersignal West Pico Chemiluminescent Substrate (Pierce), using the Gene GNOME Imager and Genesnap Imaging Software (Syngene, Frederick, MD). After the desired exposure was obtained, the membrane was stained with Ponceau Red (Fisher) to ensure equal loading of the samples. Membranes were stripped using Restore Western Stripping Buffer (Pierce, Nepean, ON) to allow for a second probing.

Pinpoint Cell Surface Protein Labeling

The Pinpoint Cell Surface Protein Isolation Kit (Pierce) was used to identify and isolate cell surface proteins following the manufacturer's instructions. In brief, control or 24 hrs lovastatin treated HUVEC cells were stimulated with or without 50 ng/ml of VEGF for 30 min. Cells were then washed with ice-cold PBS and surface proteins were biotinylated and isolated using immobilized avidin, prior to Western blot analysis of VEGFR-2 and actin levels as described above.

Phalloidin Staining/Immunofluorescence

In a 6-well flat-bottomed plate (Fisher), glass cover slips (Fisher) were placed into each well and ~250000 cells were used to seed each well. The cells were incubated overnight to allow for cell attachment and recovery. Following a 24 hr treatment of solvent control or lovastatin in serum-free media, the HUVEC cells were treated with recombinant humanVEGF165 for 30 min prior to fixation. The cells were subsequently washed with PBS then fixed with 4% paraformaldehyde (Sigma) buffered in PBS for 15 min at 37°C and stored in PBS at 4°C. To visualize actin cytoskeletal architecture, 100 µL of a 1 ng phalloidin-rhodamine conjugate in PBS was used to treat each cover slip containing the attached HUVEC cells for 15 min in the dark. Prior to immunofluorescence staining, the cells were permeabilized with PBS+0.2%Triton X-100 (Sigma) for 15 min. The cells were blocked for 30 min with PBS+3%FBS then incubated with the VEGFR-2 antibody at a dilution of 1[ratio]50 in PBS+3%FBS for an hr. The cells were then blocked with PBS+5% chicken serum (Sigma) for 30 min. Following the second blocking, the cells were incubated with Alexa Fluor 488 chicken anti-mouse IgG (Molecular Probes, Carlsbad, CA) at a working dilution of 10 µg/ml in the dark for an hr. The cells were then mounted to a microslide with DAPI mounting media (Vector Laboratories, Burlingame, CA) and analyzed under fluorescent microscopy using the Axiovision software (Allied High Tech Products, Rancho Dominguez, CA).

Rho A Activation Assay

The HUVEC and H28 cell lines were cultured in serum free media treated with 10 µM lovastatin for 24 hrs with or without 100 µM mevalonate or 10 µM GGPP. Cells were stimulated with 50 ng/ml EGF for 30 min to activate rhoA. Cell lysates were either snap frozen and stored in liquid nitrogen or used directly with the RhoA G-LISA kit (Cytoskeleton, Denver, Co) according to the manufacturer's instructions. This assay is based on the principle that a Rho-GTP-binding protein is linked to the 96-well plates. The active GTP-bound Rho in the cell lysates binds to the wells, while the inactive GDP-bound Rho is removed during the washing steps. The bound active RhoA is detected with a RhoA specific antibody and quantified by absorbance. The degree of RhoA activation is determined by comparing readings from the activated cell lysates (addition of 0.2 mM GTP) versus the non-activated cell lysates (serum starved cultures).


Technical support from Melissa Morley is greatly appreciated. We wish to thank Apotex Canada and the National Cancer Institute for generously providing reagents used in this study.


Competing Interests: The authors have declared that no competing interests exist.

Funding: The Ontario Institute for Cancer Research (574) and the Canadian Institute of Health Research (74558) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Folkman J, Kalluri R. Cancer without disease. Nature. 2004;427:787. [PubMed]
2. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674. [PubMed]
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. [PubMed]
4. Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, et al. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J Biol Chem. 2001;276:44307–44314. [PubMed]
5. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3:859–868. [PubMed]
6. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187:1579–1586. [PubMed]
7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988–26995. [PubMed]
8. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777–794. [PubMed]
9. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–475. [PubMed]
10. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109:1454–1461. [PubMed]
11. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer. 1982;49:2431–2435. [PubMed]
12. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189:72–78. [PubMed]
13. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. [PubMed]
14. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 1994;77:175–178. [PubMed]
15. Sebti S, Hamilton AD. Inhibitors of prenyl transferases. Curr Opin Oncol. 1997;9:557–561. [PubMed]
16. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacological Research. 1995;31:9–27. [PubMed]
17. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–19. [PubMed]
18. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, et al. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2003;129:631–641. [PubMed]
19. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci. 2002;115:1331–1340. [PubMed]
20. Slieker LJ, Martensen TM, Lane MD. Synthesis of epidermal growth factor receptor in human A431 cells. Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. J Biol Chem. 1986;261:15233–15241. [PubMed]
21. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, et al. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res. 2005;11:2398–2407. [PubMed]
22. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs. 2002;11:837–849. [PubMed]
23. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313:1561–1574. [PubMed]
24. Lunn JA, Wong H, Rozengurt E, Walsh JH. Requirement of cortical actin organization for bombesin, endothelin, and EGF receptor internalization. Am J Physiol Cell Physiol. 2000;279:C2019–2027. [PubMed]
25. Orth JD, Krueger EW, Weller SG, McNiven MA. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 2006;66:3603–3610. [PubMed]
26. Boulougouris P, Elder J. Epidermal growth factor receptor structure, regulation, mitogenic signalling and effects of activation. Anticancer Res. 2001;21:2769–2775. [PubMed]
27. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 2007;6:2139–2148. [PubMed]
28. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer. 2005;41:523–530. [PubMed]
29. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–491. [PubMed]
30. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 2006;26:4612–4627. [PMC free article] [PubMed]
31. Toschi A, Lee E, Xu L, Garcia A, Gadir N, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29:1411–1420. [PMC free article] [PubMed]
32. Endo A, Fukuhara S, Masuda M, Ohmori T, Mochizuki N. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal Transduct Res. 2003;23:239–254. [PubMed]
33. Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, et al. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther. 2004;3:1639–1649. [PubMed]
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. [PubMed]
35. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–6565. [PubMed]
36. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol. 2003;30:32–38. [PubMed]
37. Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008;3:1056–1064. [PubMed]
38. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood. 1999;93:1308–1318. [PubMed]
39. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001;7:158–167. [PubMed]
40. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602–3609. [PubMed]
41. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000;59:245–254. [PubMed]
42. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, et al. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene. 2010. [PubMed]
43. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, et al. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos. 1993;21:1003–1011. [PubMed]
44. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther. 2006;316:1146–1152. [PubMed]
45. Wang CY, Shui HA, Chang TC. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer. 2010;126:578–582. [PubMed]
46. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science